Form 4: Repligen Corp Director Anthony Hunt Sells Shares Under 10b5-1 Trading Plan

Director Anthony Hunt of Repligen Corp sold a significant number of shares on May 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 15, 2025, Anthony Hunt, a director of Repligen Corp, sold shares of common stock.
• The sales were executed under a 10b5-1 trading plan adopted on December 9, 2024.
• A total of 26,447 shares were sold at varying weighted average prices.
• The weighted average prices ranged from $122.66 to $127.
• Following the transactions, Hunt still beneficially owns 109,854 shares of Repligen Corp common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports insider trading activity under a pre-arranged plan, without indicating any positive or negative outlook for the company.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the sales were under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are closely watched in the biotech industry, as they can provide signals (though not always reliable) about management's confidence in the company's prospects. Sales under a 10b5-1 plan are generally less concerning than discretionary sales.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan should mitigate concerns.

Key Dates

Keywords

Repligen, RGEN, insider trading, Form 4, Anthony Hunt, 10b5-1 plan, stock sale, director